No Data
Soleosia, Morpho and others [Emerging Markets press release]
＜190A＞The development of ChordiaCTX-177 (ONO-7018) has been discontinued. ＜2937＞ Changes have been made to some contents of the Sunkus shareholder benefits. ＜3653＞ Morpho Holdings has strengthened its capital and business alliance with Mickware, which engages in the planning, development, production, and sales of computer systems. ＜4597＞ Soleidia has started patient registration for the Phase Ib/II clinical trial of SP-05. ＜9166＞ GENDA operates "TSUTAYA" in Japan.
Solexia's shareholding of over 5% by Macquarie Bank has been revealed.
It was revealed that Macquarie Bank holds more than 5% of the Stocks of Solexia <4597.T>. According to the large shareholding report submitted by Macquarie Bank after the market close on the 15th, it has been confirmed that the company holds 55.76 million shares (with a shareholding ratio of 20.44%). The purpose of the shareholding is for pure investment. The closing price on the 15th was 34 yen, up 2 yen from the previous day. Provided by Wealth Advisor.
Express News | [Large Shareholding Report] Macquarie Silver in Australia reported holding 20.44% of shares in Soleisa Pharma (4597.JP).
Solasia Pharma KK: Confirmation
Solasia Pharma KK: Financial Report - Term 17 (2024/01/01 - 2024/12/31)
Solasia Pharma to Raise 2.05 Billion Yen via Warrants to Fund SP-05 Development
